In this episode of Still Here: A two-way between Miles Griffis and Betsy Ladyzhets comparing and contrasting Long COVID and ME clinical trial designs for drugs targeting immune dysregulation and viral persistence.

The transcript for this episode can be ⁠⁠⁠found on our website⁠⁠⁠, or jump to a specific part of the podcast below:

(00:00:00) ⁠Intro⁠

(00:01:36) ⁠Recap of 2nd Keystone Symposia on Long COVID⁠

(00:20:33) Research

(00:22:48) Outro

-

Mentioned in this episode:

• The Sick Times: “The field is coming of age”: Long COVID researchers gather in Santa Fe to foster collaboration
• The Sick Times: “A morale boost”: Looking ahead to the 2025 Keystone Symposia Long COVID conference with Hannah Davis
• The Sick Times: No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential
• The Sick Times: Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation
• The Sick Times: Research updates, August 19
• The Sick Times: Covid-19 reinfections are further disabling people with Long Covid

Additional audio in this episode: 

• Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece) 
• Youtube: Keystone Symposia 2025 closing remarks